

Dr. Oliver Maria Wilbert, MBA

Job title: *Senior Director Immunotherapies*

Organisation: *Merck Serono Global Clinical Development Center*

Biography:

Dr. Wilbert is the Global Clinical Development Leader of the Muc-1 Antigen Specific Cancer Immunotherapy project STIMUVAX, currently in Phase III. He has a background in Immunology and Biochemistry. He joined Merck in 1996 building up the Bioinformatics Group. He complemented his business education with an Executive MBA in Ashridge, UK. In 2005 he served as CEO of Biovation Ltd., a biotech subsidiary of Merck in UK that was specialized in De-Immunization. In 2007 he was appointed as Global Product Team Leader for STIMUVAX. In 2010 he was appointed as Senior Director Immunotherapies co-chairing the Immunotherapy Strategy Group within Merck Serono.